ALPHAMAB-B (09966.HK) reported a profit of 0.166 billion yuan in 2024, turning a loss into a profit year-on-year.

Gelonghui reported on March 25 that ALPHAMAB-B (09966.HK) announced total revenue of 0.64 billion yuan for the year ending December 31, 2024, representing a year-on-year increase of 192.58%; it recorded a profit of 0.166 billion yuan, turning a profit compared to the previous loss; earnings per share were 0.17 yuan. The company is a leading biopharmaceutical company in China with a comprehensive proprietary technology platform in ADC, bispecific antibodies, and multifunctional protein engineering. The company's mission is to provide world-class innovative treatments for Global patients through its unique drug discovery and development capabilities.

Gelonghui FinanceMar 25 08:35 ET

Express News | Alphamab Oncology FY Revenue RMB 640.1 Million

ReutersMar 25 08:17 ET

ALPHAMAB-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 25 08:16 ET · Announcements

[Brokerage Focus] CITIC SEC: PD-L1 ADC drugs have dual efficacy and a potentially huge market size.

Jingu Financial News | CITIC SEC pointed out that PD-L1 ADC drugs have the dual efficacy of immunotherapy and targeted ADC, with a potential market size expected to benchmark against the Global market of over 50 billion USD for immunotherapeutic drugs. The positive rate of PD-L1 in several high-incidence cancer types in the USA exceeds 50%. Pfizer's PD-L1 ADC has already shown excellent efficacy in heavily treated populations with NSCLC and HNSCC, and safety is controllable. Pfizer expects to initiate 2 phase III clinical trials in 25H2, significantly increasing the certainty of R&D in this field. Domestically, HENLIUS (02696) has PD-

Jingwu Financial NewsMar 23 22:44 ET

Alphamab Oncology Gets Breakthrough Designation for Anti-Cancer Drug; Shares Surge 24%

MT NewswiresMar 18 02:55 ET

ALPHAMAB-B (09966.HK): JSKN003 has received breakthrough therapy designation from the National Medical Products Administration.

On March 18, Gelonghui announced that ALPHAMAB-B (09966.HK) released an announcement stating that JSKN003 has received breakthrough therapy designation from the National Medical Products Administration ("National Medical Products Administration") for the treatment of platinum-resistant recurrent epithelial ovarian cancer ("PROC"), primary peritoneal cancer, or fallopian tube cancer, regardless of human epidermal growth factor receptor 2 ("HER2") expression levels. This breakthrough therapy designation is based on the summarized analysis results of two clinical studies, JSKN003-101 and JSKN003-102. JSKN003-101 is a

Gelonghui FinanceMar 17 20:04 ET